Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25659071 | 0.83 | SORD (0.42) | PARP1CYP1A2POLBPRKCIP2RX7 | |
| SCHEMBL8325976 | 0.83 | KMO (0.45) | — | |
| SCHEMBL13160941 | 0.81 | MAPK1 (0.41) | POLBKMT2ATSHRIKBKBNOS3 | |
| SCHEMBL24323834 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1CDC7DBF4 | |
| SCHEMBL2465653 | 0.75 | KMT2A (0.50) | PARP1POLBKMT2AIKBKBCCNC | |
| SCHEMBL23015815 | 0.74 | CNR1 (0.41) | POLBPRKCIKMT2AKDM4EALDH1A1 | |
| SCHEMBL23015828 | 0.73 | CYP1A2 (0.38) | PARP1CYP1A2POLBPRKCIKMT2A | |
| SCHEMBL30521607 | 0.72 | ADORA3 (0.42) | PARP1KMT2AP2RX7KDM4ELMNA | |
| SCHEMBL163294 | 0.72 | KDM4E (0.37) | PARP1KMT2AP2RX7KDM4ETSHR | |
| SCHEMBL3906535 | 0.72 | ADORA3 (0.42) | PARP1KMT2AP2RX7KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292108-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | disclosed |
| CN-104981468-B | The piperazine heterocycle compound of benzimidazole 2, its pharmaceutical composition and its production and use | 上海汇伦生命科技有限公司 | 2018-01-05 | — | — | CN | disclosed |
| WO-2016177760-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885CYP1A2 763/4885POLB 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.